Transform Cancers into Manageable Conditions
Our Mission
Our mission Our mission

Adlai Nortye is a global clinical-stage biopharmaceutical company that is developing differentiated, innovative immuno-oncology medicines. Adlai Nortye focuses on discovering and developing important new treatments for cancer with a mission to improve patient lives by identifying and developing differentiated innovative medicines that help people live better, live longer. Through close collaborations with global partners, Adlai Nortye has successfully positioned itself in the field of immuno-oncology and has several programs ongoing from early pre-clinical to phase III ready.


To be a leading global presence in the immuno-oncology market
Our Vision
Our vision Our vision
Introduction to our mission
2020
Raised Nearly $100M in Series C

First Patient Dosed in Phase 1b
Clinical Trial of AN0025

Received NMPA Approval for
AN2025 Phase III Clinical Trials
Introduction to our mission
2019
Presented Encouraging Phase 1b
Study Data of AN0025 at ESMO

Received NMPA Approval for AN1004 Phase III Clinical Trials

Announced Clinical Collaboration with Merck
Introduction to our mission
2018
Opened New US Headquarters

Raised $53M in Series B

Entered into Global License
Agreement with Eisai for EP4
Antagonist
Introduction to our mission
2017
Entered into a License Agreement with Oncolytics Biotech

Entered into a Agreement with
Institue of Materia Medica
Chinese Academy of Medical
Science

Entered into a Agreement with Genor Biopharma
Introduction to our mission
2016
Raised tens of millions of RMB in Series A round of financing

Shareholding system reform
and renamed “Adlai Nortye”